1. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study
- Author
-
Todd D Swarthout, Marc Y R Henrion, Deus Thindwa, James E Meiring, Maurice Mbewe, Akuzike Kalizang’Oma, Comfort Brown, Jacquline Msefula, Brewster Moyo, Andrew A Mataya, Susanne Barnaba, Emma Pearce, Melita Gordon, David Goldblatt, Neil French, and Robert S Heyderman
- Subjects
qw_575 ,Malawi ,Vaccines, Conjugate ,Adolescent ,wa_115 ,Infant ,wc_217 ,Antibodies, Bacterial ,qw_806 ,Pneumococcal Infections ,qw_805 ,Pneumococcal Vaccines ,Infectious Diseases ,Child, Preschool ,Immunoglobulin G ,Humans ,Prospective Studies ,Child ,ws_440 ,ws_430 - Abstract
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) induce serotype-specific IgG antibodies, effectively reducing vaccine-serotype carriage and invasive pneumococcal disease (IPD). IgG production wanes approximately 1 month after vaccination in absence of serotype-specific exposure. With uncertainty surrrounding correlate of protection (CoP) estimates and with persistent vaccine-serotype carriage and vaccine-serotype IPD after PCV13 introduction, we aimed to profile population-level immunogenicity among children younger than 5 years in Blantyre, Malawi. METHODS: For this serosurveillance study, we used a random subset of samples from a prospective population-based serosurvey in Blantyre, Malawi, done between Dec 16, 2016, and June 27, 2018. Sample selection was based on age category optimisation among children younger than 5 years, adequate sample volume, and available budget. We measured serotype-specific IgGs against the 13 vaccine serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and two non-vaccine serotypes (12F and 33F), as well as IgGs against three pneumococcal proteins (PsaA, NanA, and Ply), using ELISA and a direct-binding electrochemiluminescence-based multiplex assay. We estimated population-level, serotype-specific immunogenicity profiles using a linear spline regression model. Analyses included samples stratified to 20 3-month age strata (eg, age
- Published
- 2022